In preliminary readout, GSK notches win for meningococcal vaccine
GSK said its next-generation meningococcal vaccine is just as good as currently available vaccines Bexsero and Menveo in people between the ages of 10 and 25 years old.
The new vaccine combines the strains from Bexsero and Menveo, which aim to provide protection against five variants of the disease known as A, B, C, W and Y.
The combined vaccine, MenABCWY, is currently being tested in a Phase III noninferiority trial, comparing it to the two already available vaccines. The combined vaccine is administered as two doses given six months apart to people between the ages of 10 and 25 years old, compared to the combination of one dose of Menveo and two doses of Bexsero. According to GSK, the strains in the combined vaccine account for 95% of those circulating in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.